tbuckley/cabot-search huggingface dataset:
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk
Authors: Scott D. Neidich, Youyi Fong, Shuying S. Li, Daniel E. Geraghty, Brian D. Williamson, William Chad Young, Derrick Goodman, Kelly E. Seaton, Xiaoying Shen, Sheetal Sawant, Lu Zhang, Allan C. deCamp, Bryan S. Blette, Mengshu Shao, Nicole L. Yates, Frederick Feely, Chul-Woo Pyo, Guido Ferrari, Ian Frank, Shelly T. Karuna, Edith M. Swann, John R. Mascola, Barney S. Graham, Scott M. Hammer, Magdalena E. Sobieszczyk, Lawrence Corey, Holly E. Janes, M. Juliana McElrath, Raphael Gottardo, Peter B. Gilbert, Georgia D. Tomaras
Journal: Journal of Clinical Investigation (2019)

HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered persons who have sex with men in the United States. Identified immune correlates of lower HIV-1 risk and a virus sieve analysis revealed that, despite lacking overall efficacy, vaccine-elicited responses exerted pressure on infecting HIV-1 viruses. To interrogate the mechanism of the antibody correlate of HIV-1 risk, we examined antigen-specific antibody recruitment of Fcγ receptors (FcγRs), antibody-dependent cellular phagocytosis (ADCP), and the role of anti-envelope (anti-Env) IgG3. In a prespecified immune correlates analysis, antibody-dependent monocyte phagocytosis and antibody binding to FcγRIIa correlated with decreased HIV-1 risk. Follow-up analyses revealed that anti-Env IgG3 breadth correlated with reduced HIV-1 risk, anti-Env IgA negatively modified infection risk by Fc effector functions, and that vaccine recipients with a specific FcγRIIa single-nucleotide polymorphism locus had a stronger correlation with decreased HIV-1 risk when ADCP, Env-FcγRIIa, and IgG3 binding were high. Additionally, FcγRIIa engagement correlated with decreased viral load setpoint in vaccine recipients who acquired HIV-1. These data support a role for vaccine-elicited anti–HIV-1 Env IgG3, antibody engagement of FcRs, and phagocytosis as potential mechanisms for HIV-1 prevention.
Cost avoidance through the medically integrated dispensary for oral chemotherapy: Utilizing the NCODA cost avoidance and waste tracker.
Authors: Joshua Nubla, Nancy J. Egerton
Journal: Journal of Clinical Oncology (2018)

e18916 Background: Quality care within oral oncology dispensing through medically integrated dispensaries (MID) create proactive interventions which can be significantly impactful but often go unmeasured. MIDs strive to function within OCM by improving quality of care and reducing costs through cost avoidance. The National Community Oncology Dispensing Association (NCODA) sought to measure cost avoidance within an MID versus the waste produced by specialty/mail order pharmacies. NCODA created a web-tool known as the Cost Avoidance/Waste Tracker that was made available to the NCODA oncology membership to assist in quantifying this form of positive intervention. Methods: This is a cost analysis of medication costs from voluntary data entries provided by NCODA member practices across the United States over 16 months from 2016-2018. Monetary outcomes were calculated using the NCODA Cost Avoidance/Waste Tracker tool which utilizes average wholesale price (AWP). A total of 470 eligible data entries were included for analysis. Cost Avoidance was defined as interventions that are made, before a drug is dispensed to the patient, that preclude an unnecessary prescription from being filled and dispensed. Waste was defined as drugs that have been processed or prescriptions filled and then for any reason, the drug is not used by the patient. Results: Current results place total cost avoidance at over $3.1 million and over $1.9 million in total reported waste caused by specialty/mail order pharmacy. The approximated average amount of cost avoidance was $9,500 per cost avoidance event recorded and $13,682 per event recorded for waste produced from specialty/mail order distribution. For the 22 initial practices involved there was an average voluntary reported cost avoidance of $141,202 per practice and reported waste of $87,071 per practice, with a positive net of $54,130 cost avoidance per practice. Conclusions: The results display a significant impact that MIDs have in cost avoidance interventions vs. the waste produced from other forms of oncology distribution and warrants further study to uncover the financial influence and positive change that MIDs can bring to the oncology marketplace.
Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population
Authors: S Tun Min, A. Roohullah, A. Tognela, A. Jalali, M. Lee, R. Wong, J. Shapiro, M. Burge, D. Yip, L. Nott, A. Zimet, B. Lee, A. Dean, S. Steel, H.-L. Wong, P. Gibbs, S H-S Lim
Journal: Annals of Oncology (2019)
Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Authors: D.L. Sarid, R. Berger, M. Levertovsky, M. Gadot, C. Maurice-Dror, A. Peer, R. Perets, O. Purim, M. Sarfaty, E. Rosenbaum, V. Neiman, H. Ligumsky, K. Rouvinov, E. Romanov, W. Marmelstein, N. Shani-Shrem, G. Weiner, R. Leibowitz-Amit
Journal: Annals of Oncology (2019)
High flow through nasal cannula in exacerbated COPD patients: a systematic review
Authors: L. Pisani, M. Astuto, I. Prediletto, F. Longhini
Journal: Pulmonology (2019)

Chronic Obstructive Pulmonary Disease (COPD) history is characterized by episodes of exacerbation of varying severity, featured by acute worsening of respiratory symptoms, commonly precipitated by respiratory tract infection. The recent ERS/ATS clinical practice guidelines strongly recommend the application of non invasive ventilation (NIV) for patients with acute respiratory failure (ARF) leading to acute or acute-on-chronic respiratory acidosis (pH 7.35) and not for those patients with acute exacerbation of COPD (AECOPD) and hypercapnia who are not acidotic. In recent years, High-Flow through Nasal Cannula (HFNC) has been introduced in the clinical practice. We designed the present systematic review of the literature to assess all effects of HFNC use reported in exacerbated COPD patients. In this setting, HFNC is able to keep PaCO2 unmodified, while oxygenation slightly deteriorates as opposed to NIV. Furthermore, the work of breathing is reduced with HFNC by a similar extent to NIV, while it increases by 40–50% during conventional oxygen therapy (COT). HFNC is also reported to be more comfortable than COT and NIV. Despite these results, little and limited evidence for improved clinical outcomes is currently available.
Abstract 18079: Targeted Use of Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure
Authors: Ian C Chang, Angela Dispenzieri, Grace Lin, Barry Karon, Allan S Jaffe, Kyle Klarich, Martha Grogan
Journal: Circulation (2017)

Introduction: Light-chain amyloidosis (AL) is a rare disease with a prevalence of 8-10/million patient years. Cardiac AL is associated with poor prognosis if left untreated and its true prevalence ...
Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance
Authors: S. Michels, B. Massuti Sureda, H.-U. Schildhaus, J. Franklin, M. Sebastian, E. Felip, C. Grohe, D.F. Rodríguez-Abreu, H. Bischoff, E. Carcereny Costa, J. Corral Jaime, A. Insa, M. Reck, M. Scheffler, N. Karachaliou, S. Merkelbach-Bruse, L. Nogova, R. Büttner, R. Rosell, J. Wolf
Journal: Annals of Oncology (2019)
COMPRAYA: Dutch nationwide infrastructure for COMPRehensive health outcome and intervention research among patients with adolescent and young adult cancer
Authors: O. Husson, M. Ligtenberg, L.V. van de Poll-Franse, J.B. Prins, M.J. van den Bent, M.C. van Eenbergen, E. Manten-Horst, R.M. Bijlsma, S.J.E. Kaal, J.M. Tromp, A. Verschoor, M E M M Bos, J. Nuver, Y. Jauw, R.I. Lalisang, S. Sleeman, C. Vlooswijk, J.A. Gietema, W.T. van der Graaf
Journal: Annals of Oncology (2019)
High Incidence of Late, Sustained and Clinically Inconsequential Epstein Barr Virus (EBV) Reactivation Following Combined Unrelated Cord Blood and Haploidentical CD34+ Cell Transplantation
Authors: Sneha Purvey, Enkhtsetseg Purev, Xin Tian, Jennifer Wilder, Lisa Cook, Catalina Ramos, Elena Cho, Patricia Prince, Susan F. Leitman, Hanh Khuu, David Stroncek, Robert N Reger, Georg Aue, Richard W. Childs
Journal: Blood (2014)
Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT)
Authors: H. Riess, J. Braverman, M. Reni, A.C. Dueck, A. Hendifar, D.-Y. Oh, C.-P. Li, T Macarulla Mercade, A. Shah, N. Joshi, M. Botterman, E. Mantovani, B. Lu, M.A. Tempero
Journal: Annals of Oncology (2019)
Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Authors: M. Cho, J.C. Bendell, S.-W. Han, J. Naidoo, C. Lieu, B.A. Carneiro, E. Varga, X. Li, P. Kourtesis, S.E. Abdullah, S. Patel
Journal: Annals of Oncology (2019)
Association between meteorological variations and activities of influenza A and B across different climate zones: a multi-region modelling analysis across the globe
Authors: Ka Chun Chong, Tsz Cheung Lee, Seweryn Bialasiewicz, Jian Chen, David W. Smith, Wisely S.C. Choy, Mel Krajden, Hamid Jalal, Lance Jennings, Burmaa Alexander, Hong Kai Lee, Pieter Fraaij, Avram Levy, Apple C.M. Yeung, Sarah Tozer, Steven Y.F. Lau, Katherine M. Jia, Julian W.T. Tang, David S.C. Hui, Paul K.S. Chan
Journal: Journal of Infection (2019)
Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice
Authors: Yunhuan Liu, Kefei Chen, Fengyuan Li, Zelin Gu, Qi Liu, Liqing He, Tuo Shao, Qing Song, Fenxia Zhu, Lihua Zhang, Mengwei Jiang, Yun Zhou, Shirish Barve, Xiang Zhang, Craig J. McClain, Wenke Feng
Journal: Hepatology (2019)

Cholestatic liver disease is characterized by gut dysbiosis and excessive toxic hepatic bile acids (BAs). Modification of gut microbiota and repression of BA synthesis are potential strategies for the treatment of cholestatic liver disease. The purpose of this study was to examine the effects and to understand the mechanisms of the probiotic Lactobacillus rhamnosus GG (LGG) on hepatic BA synthesis, liver injury, and fibrosis in bile duct ligation (BDL) and multidrug resistance protein 2 knockout (Mdr2-/- ) mice.Global and intestine-specific farnesoid X receptor (FXR) inhibitors were used to dissect the role of FXR. LGG treatment significantly attenuated liver inflammation, injury, and fibrosis with a significant reduction of hepatic BAs in BDL mice. Hepatic concentration of taurine-β-muricholic acid (T-βMCA), an FXR antagonist, was markedly increased in BDL mice and reduced in LGG-treated mice, while chenodeoxycholic acid, an FXR agonist, was decreased in BDL mice and normalized in LGG-treated mice. LGG treatment significantly increased the expression of serum and ileum fibroblast growth factor 15 (FGF-15) and subsequently reduced hepatic cholesterol 7α-hydroxylase and BA synthesis in BDL and Mdr2-/- mice. At the molecular level, these changes were reversed by global and intestine-specific FXR inhibitors in BDL mice. In addition, LGG treatment altered gut microbiota, which was associated with increased BA deconjugation and increased fecal and urine BA excretion in both BDL and Mdr2-/- mice. In vitro studies showed that LGG suppressed the inhibitory effect of T-βMCA on FXR and FGF-19 expression in Caco-2 cells.LGG supplementation decreases hepatic BA by increasing intestinal FXR-FGF-15 signaling pathway-mediated suppression of BA de novo synthesis and enhances BA excretion, which prevents excessive BA-induced liver injury and fibrosis in mice.
Early signs of clinical activity in Aml patients receiving NKG2D CAR T cell therapy in the absence of pre-conditioning chemotherapy : an alternative strategy to CAR T cell therapy
Authors: Eytan Breman, David A Sallman, Jason B Brayer, Xavier Poire, Tessa Kerre, Philippe Lewalle, Eunice S Wang, Bikash Verma, Marco L Davila, Nathalie Braun, Caroline Lonez, Frederik Lehmann, David E Gilham
Journal: Molecular Therapy (2018)
RTHP-41. LONG-TERM STROKE RISK IN MENINGIOMA PATIENTS TREATED WITH CONVENTIONALLY FRACTIONATED PHOTON-BASED RADIATION THERAPY
Authors: Shearwood McClelland III, Timur Mitin, Charlotte Kubicky, Jerry Jaboin
Journal: Neuro-Oncology (2018)

Fractionated radiotherapy (RT) has been a stalwart treatment modality for intracranial meningioma for decades, providing excellent tumor control. The increasing access to proton therapy and theoretical advantages based on physical properties are likely to lead to increased number of patients with meningioma and other intracranial tumors receiving proton-beam RT. A recent randomized study of RT from the Massachusetts General Hospital involving an 80% to 20% proton/photon ratio during treatment for subtotally resected/recurrent benign meningioma patients found the risk of stroke was 20.5%, with the average stroke developing 5.6 years after RT completion (Sanford et al., 2017). The long-term stroke risk in patients with meningioma treated with photon-based fractionated RT has not been previously studied. A PubMed database search for relevant articles examining photon-based RT for meningioma with minimum mean/median follow-up of six years was undertaken. Stroke rate was assessed either from direct description in manuscripts, or from extrapolating post-RT complications from reported clinical examinations (i.e. hemiparesis/weakness, pituitary dysfunction following treatment of cavernous sinus lesions). Results were then culled to determine an overall stroke rate. Six studies met inclusion criteria; 303 patients received photon-based RT for meningioma with a sufficient long-term follow-up. Median/mean follow-up ranged from 78–168 months. Operative resection prior to RT occurred in 213 patients (70.3%). Seventeen patients suffered a stroke following RT, yielding a rate of 5.6%. CONCLUSIONS: The long-term stroke risk in patients with meningioma treated with photon-based conventionally fractionated RT appears to be significantly lower than the stroke rate reported in a randomized phase III trial utilizing a 80/20 combination of protons and photons. Future studies are necessary to determine if photon-based therapy may actually be safer for patients with intracranial diseases, such as benign meningioma.
An unbiased approach de-livers unexpected insight into torsin biology
Authors: Sarah M. Prophet, Christian Schlieker
Journal: Journal of Clinical Investigation (2019)

Mutations affecting the integrity of the essential torsin ATPase/cofactor system have been identified in a steadily increasing number of congenital disorders. Since most of these mutations affect brain function, much of the research has focused on deciphering disease etiology in the brain. However, torsin is expressed in a wide variety of nonneural tissues and is strictly conserved across species, including the lowest metazoans, suggesting that it plays roles extending beyond neurons. In this issue of the JCI, Shin et al. explored torsin function in the mammalian liver. The group reports major defects in hepatic lipid metabolism when the torsin system is compromised in mice. Remarkably, conditional deletion of either torsinA or its cofactor, lamina-associated polypeptide 1 (LAP1), resulted in fatty liver disease and steatohepatitis, likely from a secretion defect of VLDLs. This study considerably expands our understanding of torsin biology, while providing defined opportunities for future investigations of torsin function and dysfunction in human pathologies.
Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Authors: T.Y. Semiglazova, M. Osipov, P. Krivorotko, V. Semiglazov, S. Protsenko, L. Berstein, E. Tsirlina, V. Klimenko, R. Donskih, V. Anisimov, A. Belyaev
Journal: Annals of Oncology (2019)
Severe oral mucositis (SOM) mitigation by genetically modified lactococcus lactis bacteria (LLB) producing human trefoil factor 1 (hTFF1; AG013) in patients being treated with concomitant chemoradiation (CRT) for oral and oropharyngeal cancers (OCOPC)
Authors: S. Singh, S. Nuyts, R. Doline, S. Satti, M. Schwartz, S. Thatcher, Y. Chen, S. Katz, M. Garg, J. Wagemans, P. Specenier, C. Wittekindt, L. Lee, J. Reifler, S. Sonis, M. Emanuel, F. Cilli, A. Joslyn, J. Wade
Journal: Annals of Oncology (2019)
TCT-502 Are pharmaco invasive therapy results after 6 hours of symptoms onset adequate? how do they compare with those treated with less than 6 hours?
Authors: Marco Tulio Souza, Joao Pereira, Beatriz Paiva, Suzi Kawakami, Rafaela Oliveira, Renato Oliveira, Nara Almeida, Roberto Filho, Pedro Ivo de Marqui Morais, Guilherme Cintra, Antonio Moreno, Adriano Barbosa, Adriano Caixeta, Jose Marconi Almeida Sousa, Iran Gonçalves, Claudia Alves, Antonio Carvalho
Journal: Journal of the American College of Cardiology (2018)
Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients
Authors: M. Del Re, V. Conteduca, S. Crucitta, G. Gurioli, C. Casadei, G. Restante, G. Schepisi, C. Lolli, R. Morganti, R. Danesi, U.F.F. De Giorgi
Journal: Annals of Oncology (2019)
Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
Authors: E. Moati, H. Blons, V. Taly, F. Garlan, W.-R. Shu-Fang, D. Pietrasz, A. Didelot, S. Garrigou, A. Saint, S. Pernot, J. Taieb, P. Laurent-Puig, A. Zaanan
Journal: Annals of Oncology (2019)
A System of Medicine by Many Writers.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Authors: M. Brahmi, T. Franceschi, I. Treilleux, D. Pissaloux, I.L. Ray-Coquard, A. Dufresne, P. Meeus, M.-P. Sunyach, K. Marie, A. Meurgey, J.-Y. Blay, F. Tirode
Journal: Annals of Oncology (2019)
Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Authors: T. Rampias, L. Hoxhallari, M. Avgeris, Z. Kanaki, D. Telios, E. Giotakis, I. Giotakis, A. Scorilas, A. Psyrri, A. Klinakis
Journal: Annals of Oncology (2019)
A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms
Authors: Alessandro Rambaldi, Chiara Maria Dellacasa, Silvia Salmoiraghi, Orietta Spinelli, Maria Luisa Ferrari, Elisabetta Gattoni, Paola Guglielmelli, Alessandro M. Vannucchi, Giovanni Barosi, Tiziano Barbui
Journal: Blood (2008)
Liquid biopsy in clinical pratice of non-small cell lung cancer (NSCLC): A multi-institutional experience
Authors: G. De Maglio, G. Pasello, A. Follador, G. Nardo, F. Cortiula, A.l. De Conte, A. D’Urso, G. Petros, S. Girlando, M. Miorin, V. Polo, E. Scquizzato, G. Settanni, V. Picece, A. Veccia, S. Indraccolo
Journal: Annals of Oncology (2019)
Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial)
Authors: M. Hecht, A.-O. Gostian, M. Eckstein, S. Rutzner, J. von der Grün, T. Illmer, M.G. Hautmann, T. Brunner, S. Laban, G. Klautke, B. Tamaskovics, B. Frey, A. Hartmann, C. Rödel, W. Budach, U. Gaipl, H. Iro, R. Fietkau
Journal: Annals of Oncology (2019)
Clinical Significance of AR-V567es in Prostate Cancer—Response
Authors: Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi, Giuseppe Galletti, Paraskevi Giannakakou
Journal: Clinical Cancer Research (2019)

We thank Drs. Plymate and Uo for their assessment of the article by Bernemann and colleagues ([1][1]) and for sharing their concerns about the validity of the AR-v567es assay used in our study ([2][2]).

The intent of Bernemann and colleagues was to compare six published assays for the detection of
MONARCHplus: A phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2- advanced breast cancer (ABC)
Authors: Z. Jiang, X. Hu, Q. Zhang, T. Sun, Y. Yin, H. Li, R. Costa, M. Yan, C. Oppermann, Z. Tong, Y. Liu, Y. Zhang, Y. Cheng, Q. Ouyang, X. Chen, N. Liao, X. Wu, X. Wang, R. Han, Y. Lu
Journal: Annals of Oncology (2019)
Abstract 15266: Nanoparticle-Mediated Simultaneous Targeting of Mitochondria and Inflammatory Monocytes Attenuates Cerebral Ischemia-Reperfusion Injury in Mice
Authors: Arihide Okahara, Tetsuya Matoba, Jun-ichiro Koga, Masaki Fujiwara, Daiki Funamoto, Kaku Nakano, Hiroyuki Tsutsui, Kensuke Egashira
Journal: Circulation (2017)

Introduction: The early reperfusion is a principal therapeutic strategy for the treatment of acute cerebral infarction. Opening of mitochondrial permeability transition pore (mPTP), regulated by cy...
Tumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase III INNOVATE-3/ENGOT-ov50 study
Authors: I.B. Vergote, L. Copeland, B.J. Monk, R.L. Coleman, D. Cibula, J. Sehouli, E.P. Samartzis, M. Radoslaw, A González Martín, J. Korach, V. Salutari, P.O. Witteveen, D. O’Malley
Journal: Annals of Oncology (2019)
Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)
Authors: J. O’Shaughnessy, L.A. Emens, S. Chui, K. Russell, S.-W. Lin, C Flores Avile, P. Luhn, A. Schneeweiss
Journal: Annals of Oncology (2019)
Untargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
Authors: M. Balic, C. Suppan, I. Brcic, V. Tiran, D.H. Mueller, F. Posch, P. Ulz, E. Heitzer, N. Dandachi
Journal: Annals of Oncology (2019)
Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung
Authors: D.M. Kowalski, A. Morabito, A. Montanino, R. Bernabé, F. Grossi, R. Ramlau, T.-E. Ciuleanu, G.L. Ceresoli, G. Pasello, F. de Marinis, J. Bosch Barrera, P. Landreau, S. Gautier, C. Ta Thanh Minh, A. Camerini
Journal: Annals of Oncology (2019)
Clinical Benefit and Improvement of Mitochondrial Function in Low Risk Myelodysplastic Syndrome Treated By Combination Ultra Coenzyme Q10 and L-Carnitine
Authors: Kalman Filanovsky, Michal Haran, Vita Mirkin, Andrei Braester, Olga Shvetz, Anfisa Stanevsky, Erica Sigler, Ekaterina Votinov, Yehudit Zaltsman-Amir, Atan Gross, Lev Shvidel
Journal: Blood (2017)